全部资讯｜CELL INTELLIGENCE

T-Cell Engagers Targeting BCMA, GPRC5D, or FcRH5 in Relapsed/Refractory Multiple Myeloma: The Landscape Beyond CAR-T Cell Therapy-A Systematic Review

PubMed 2026/08/11 发表Int J Mol SciQ1 · IF 5.6（JCR 2025）

Endless possibilities and how to exploit them? What is the optimal treatment sequence?

PubMed 2025/12/05 发表Hematology Am Soc Hematol Educ ProgramQ1 · IF 3.7（JCR 2025）

Revolutions at the frontline of multiple myeloma treatment: lessons and challenges to finding a cure.

PubMed 2025/06/20 发表Front OncolQ2 · IF 3.4（JCR 2025）

Advancements in bispecific antibodies for multiple myeloma: What's new and what lies ahead.

PubMed 2024/12/30 发表Semin HematolQ1 · IF 4.3（JCR 2025）

Novel Approaches of Cellular Therapy in Multiple Myeloma: Focus on Chimeric Antigen Receptor T-Cells.

PubMed 2024/12/28 发表Acta HaematolQ2 · IF 2.8（JCR 2025）

CAR-T 细胞疗法在多发性骨髓瘤治疗中显示出显著获益。

Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins.

PubMed 2024/07/03 发表Nat Rev Clin OncolQ1 · IF 94.6（JCR 2025）

Current Novel Targeted Therapeutic Strategies in Multiple Myeloma.

PubMed 2024/06/04 发表Int J Mol SciQ1 · IF 5.6（JCR 2025）

Bispecific antibodies for the treatment of relapsed/refractory multiple myeloma: updates and future perspectives.

PubMed 2024/04/10 发表Front OncolQ2 · IF 3.4（JCR 2025）

T cell redirecting bispecific antibodies for multiple myeloma: emerging therapeutic strategies in a changing treatment landscape.

PubMed 2022/09/05 发表Leuk LymphomaQ3 · IF 2.1（JCR 2025）

全部资讯 9